Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Young, Pamela
Fallon, Lara
Mundayat, Rajiv
Dina, Oluwaseyi
Blachley, Taylor
Middaugh, Nicole
Ogdie, Alexis
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
https://doi.org/10.1007/s40744-023-00631-4
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 3 August 2023
Accepted: 6 December 2023
First Online: 22 January 2024
Declarations
:
: Philip J. Mease has acted as a consultant for and/or has received grant/research support from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Eli Lilly, Galapagos, Gilead Sciences, Inmagene, Janssen, MoonLake, Novartis, Pfizer Inc, Sun, and UCB. Pamela Young, Lara Fallon, Rajiv Mundayat, and Oluwaseyi Dina are employees and stockholders of PfizerĀ Inc. Taylor Blachley and Nicole Middaugh are employees of CorEvitas, LLC. Alexis Ogdie is a stockholder of Amgen, Novartis, and Pfizer Inc, and has received grant/research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Eli Lilly, Novartis, and Pfizer Inc.
: The study was performed in accordance with Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (No. 120160939). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating in the study.